
VolitionRx Partners with Sysmex to Scale Epigenetic Diagnostics
VolitionRx has entered a strategic partnership with global diagnostics firm Sysmex to integrate its proprietary Nu.Q® NETs H3.1 assay into the Japanese company’s existing analyzer infrastructure. The collaboration targets the multibillion-dollar market for monitoring diseases linked to NETosis, including sepsis and various acute inflammatory conditions.









.png)















